# STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

> **NCT04616027** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 42 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Renal Impairment
- Healthy

## Interventions

- **DRUG:** PF-06882961 20 mg

## Key facts

- **NCT ID:** NCT04616027
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-13
- **Primary completion:** 2022-02-18
- **Final completion:** 2022-02-18
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2024-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04616027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04616027, "STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04616027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*